Safety, pharmacokinetics and pharmacodynamics of remogliflozin etabonate, a novel SGLT2 inhibitor, and metformin when co-administered in subjects with type 2 diabetes mellitus.
about
Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors from Natural Products: Discovery of Next-Generation Antihyperglycemic AgentsRandomized trial showing efficacy and safety of twice-daily remogliflozin etabonate for the treatment of type 2 diabetes.Randomized efficacy and safety trial of once-daily remogliflozin etabonate for the treatment of type 2 diabetes.Dapagliflozin: a sodium glucose cotransporter 2 inhibitor in development for type 2 diabetes.Development and potential role of type-2 sodium-glucose transporter inhibitors for management of type 2 diabetes.Remogliflozin etabonate: a novel SGLT2 inhibitor for treatment of diabetes mellitus.The antidiabetic drug metformin decreases mitochondrial respiration and tricarboxylic acid cycle activity in cultured primary rat astrocytes.The potential of SGLT2 inhibitors in phase II clinical development for treating type 2 diabetes.Comparative pharmacokinetics of three SGLT-2 inhibitors sergliflozin, remogliflozin and ertugliflozin: an overview.Limited sampling strategy for determining metformin area under the plasma concentration-time curve.Remogliflozin Etabonate Improves Fatty Liver Disease in Diet-Induced Obese Male MiceOverview of clinically approved oral antidiabetic agents for the treatment of type 2 diabetes mellitus.
P2860
Q28074843-077928BC-F5E4-44E4-B0C4-943DEE7914C3Q34438769-07642DAD-FBCE-406F-BB1E-43084412D51BQ34439528-8B15EA06-3082-4519-A19C-B0A084FCA48EQ35111555-9AD10A81-CE5C-474A-8B12-C53525E97343Q35214420-67CFFB28-35B8-42DB-933A-C308394DBCCFQ38569449-6804B204-BF57-454A-8AA4-B57C3A261336Q38896048-6A8EDE68-7997-4623-AEC5-1DE907181890Q38908779-45B21625-26EB-4489-84FC-7250EC0E3C16Q38975736-F3B0D950-B00D-4C9B-89E5-B3D55BE982B5Q39669192-953B153F-FAD2-4F51-ABA2-BF02A8AFA49EQ42107886-FA2904B3-96C6-465B-85D4-A0145CE5ED6AQ46207930-37B20074-A7FC-4D9A-8C11-17C6C136F065
P2860
Safety, pharmacokinetics and pharmacodynamics of remogliflozin etabonate, a novel SGLT2 inhibitor, and metformin when co-administered in subjects with type 2 diabetes mellitus.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Safety, pharmacokinetics and p ...... with type 2 diabetes mellitus.
@en
type
label
Safety, pharmacokinetics and p ...... with type 2 diabetes mellitus.
@en
prefLabel
Safety, pharmacokinetics and p ...... with type 2 diabetes mellitus.
@en
P2093
P2860
P356
P1476
Safety, pharmacokinetics and p ...... with type 2 diabetes mellitus
@en
P2093
Anita Kapur
Bryan Rafferty
Charles D James
Elizabeth K Hussey
Robert L Dobbins
Robin O'Connor-Semmes
P2860
P2888
P356
10.1186/2050-6511-14-25
P577
2013-04-30T00:00:00Z
P5875
P6179
1010574474